B. Metzler seel. Sohn & Co. AG Makes New $2.55 Million Investment in Revolution Medicines, Inc. $RVMD

Key Points

• B. Metzler seel. Sohn & Co. AG acquired 13,605 Revolution Medicines shares worth approximately $2.55 million during the second quarter. Institutional investors collectively own 94.34% of RVMD.
• Analysts remain broadly bullish, with an average “Moderate Buy” rating and a consensus price target of $167.89, although targets range as high as $230 and one firm maintains a sell rating.
• RVMD shares opened at $209.46 after reaching a 52-week high of $220.34, while the company reported a quarterly loss of $3.06 per share—worse than the expected $2.04 loss. Insiders sold 132,497 shares worth $21.47 million over the past three months, primarily to cover tax obligations on vested equity awards.

B. Metzler seel. Sohn & Co. AG purchased a new position in shares of Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 13,605 shares of the company's stock, valued at approximately $2,548,000.

A number of other large investors have also made changes to their positions in RVMD. Meeder Advisory Services Inc. boosted its holdings in Revolution Medicines by 3.0% during the first quarter. Meeder Advisory Services Inc. now owns 4,126 shares of the company's stock worth $401,000 after buying an additional 120 shares in the last quarter. PNC Financial Services Group Inc. increased its holdings in Revolution Medicines by 1.3% in the fourth quarter. PNC Financial Services Group Inc. now owns 10,066 shares of the company's stock valued at $802,000 after buying an additional 125 shares in the last quarter. Deutsche Bank AG lifted its position in shares of Revolution Medicines by 0.4% during the 4th quarter. Deutsche Bank AG now owns 32,217 shares of the company's stock valued at $2,566,000 after acquiring an additional 130 shares during the period. Contravisory Investment Management Inc. acquired a new stake in shares of Revolution Medicines during the 2nd quarter valued at approximately $32,000. Finally, Johnson Financial Group Inc. purchased a new stake in shares of Revolution Medicines during the 2nd quarter worth approximately $37,000. Hedge funds and other institutional investors own 94.34% of the company's stock.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the company. Wedbush upped their price target on Revolution Medicines from $192.10 to $201.00 and gave the stock an "outperform" rating in a report on Thursday, August 6th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Revolution Medicines in a research report on Friday, July 17th. Evercore reissued an "outperform" rating and issued a $230.00 target price on shares of Revolution Medicines in a report on Thursday, August 6th. HC Wainwright restated a "buy" rating and issued a $195.00 price target on shares of Revolution Medicines in a research report on Monday, July 6th. Finally, Piper Sandler raised their price target on Revolution Medicines to $172.00 and gave the company an "overweight" rating in a research report on Thursday, May 7th. One investment analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Revolution Medicines has an average rating of "Moderate Buy" and an average target price of $167.89.

Revolution Medicines Stock Down 1.1%

Shares of NASDAQ:RVMD opened at $209.46 on Friday. The company has a quick ratio of 11.38, a current ratio of 11.38 and a debt-to-equity ratio of 0.40. Revolution Medicines, Inc. has a 52-week low of $35.62 and a 52-week high of $220.34. The stock's fifty day simple moving average is $187.99 and its 200-day simple moving average is $144.50. The company has a market capitalization of $44.90 billion, a P/E ratio of -23.75 and a beta of 1.39.

Revolution Medicines (NASDAQ:RVMD - Get Free Report) last issued its quarterly earnings results on Wednesday, August 5th. The company reported ($3.06) EPS for the quarter, missing analysts' consensus estimates of ($2.04) by ($1.02). During the same period last year, the firm posted ($1.31) EPS. As a group, equities research analysts forecast that Revolution Medicines, Inc. will post -8.82 earnings per share for the current fiscal year.

Insider Activity

In other Revolution Medicines news, insider Mark A. Goldsmith sold 10,020 shares of the firm's stock in a transaction dated Tuesday, June 16th. The stock was sold at an average price of $156.12, for a total value of $1,564,322.40. Following the sale, the insider directly owned 267,330 shares of the company's stock, valued at approximately $41,735,559.60. This trade represents a 3.61% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, COO Margaret A. Horn sold 60,400 shares of Revolution Medicines stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $160.17, for a total value of $9,674,268.00. Following the completion of the sale, the chief operating officer owned 158,222 shares of the company's stock, valued at $25,342,417.74. This trade represents a 27.63% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 132,497 shares of company stock valued at $21,470,486 in the last three months. Company insiders own 7.60% of the company's stock.

About Revolution Medicines

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company's research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source